Merck & Co
Merck & Co

Merck & Co

Pharmaceuticals
WebsiteInvestor RelationsSEC
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).

$362.4B

Market Cap • 9/18/2026

1970

(56 years)

Founded

1949

(77 years ago)

IPO

NYSE

Listing Exchange

Flag of United States

United States

Country

S&P500 Participant

Index Composite • 2026

Valuation

P/B

8,6

P/S

5,4

P/EBITDA

27,7

P/OCF

18,1

P/FCF

22,6

P/E

117,5

BVPS

16,9

EPS

1,3

Market Cap

Market Cap

362,4B

EV

409,2B

EV/Revenue

6,1

EV/EBITDA

31,2

EV/EBIT

64,1

Payout

Dividend Per Share

3,3

Dividend Yield

2,3%

Buyback Yield

1,1%

Total Yield

3,4%

Dividend Yield 5Y

2,8%

Payout

261,5%

Retained Earnings

63,3B

Profitability

Gross Margin

73%

EBITDA Margin

19,7%

EBIT Margin

9,6%

Net Margin

4,8%

D&A/EBITDA

0%

R&D/Revenue

45,7%

Capex/Revenue

5,9%

Capex/D&A

58,1%

Capex/OCF

19,6%

SBC/OCF

4,5%

% PPE

19,8%

% Goodwill

16,6%

ROE

7%

ROIC

3,7%

Growth

CAGR Revenue 5Y

8,7%

CAGR Op. Income 5Y

11,3%

CAGR Net Income 5Y

-2,9%

CAGR EPS 5Y

-6,5%

CAGR OCF 5Y

54,9%

Leverage

N.D./EBITDA

3,6

Debt/Equity

0%

Current Ratio

1,3

Quick Ratio

0,7

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium